Astellas Pharma Inc (ALPMY) 15.2650 $ALPMY Pfizer (PFE)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Astellas Pharma Inc (ALPMY) 15.2650 $ALPMY

Pfizer (PFE) Bought Medivation (MDVN), but is it a Good Deal?
Maher Syed - Zacks Investment Research - Mon Aug 22, 4:06PM CDT
Pfizer is paying $14 billion for Medivation Inc, but is it worth it?
MDVN: 80.56 (+0.20), PFE: 34.80 (-0.08), SNY: 38.47 (-0.31)

Cytokinetics' Amyotrophic Lateral Sclerosis Study Enrolled
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 9:13AM CDT
Cytokinetics (CYTK) reported that it has completed patient enrollment in the phase III amyotrophic lateral sclerosis study on tirasemtiv.
CYTK: 12.07 (-0.02), AMGN: 170.06 (-0.70)

Sanofi's Bid for Medivation Is Too Low
Todd Campbell, The Motley Fool - Motley Fool - Thu Apr 28, 1:38PM CDT
Image source: Flickr user StockMonkeys.com. After waiting for weeks for a reply to its M&A offer, drug giant Sanofi has gone public with a $9.3 billion bid to acquire mid-cap cancer drugmaker Medivation  . Sanofi's purchase price is...
MDVN: 80.56 (+0.20), JNJ: 119.34 (-0.13), GILD: 78.38 (+0.46), SNY: 38.47 (-0.31), NVS: 78.77 (-0.57)

J&J's Q1 Results Suggest More Upside for Medivation, Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 27, 7:01AM CDT
SOURCE: JOHNSON & JOHNSON Johnson & Johnson has reported its first-quarter financials, and the report shows that market share for its top selling prostate cancer drug Zytiga slipped slightly in the quarter. The loss of market share in...
MDVN: 80.56 (+0.20), JNJ: 119.34 (-0.13)

Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 10:50AM CDT
Medivation (MDVN) and Astellas (ALPMY) announced that the EMA's CHMP has issued a positive opinion in favor of the inclusion of new data in Xtandi's label.
MDVN: 80.56 (+0.20), AZN: 32.81 (-0.40), AMAG: 23.83 (-0.06)

Medivation Prostate Cancer Drug Xtandi under Pricing Attack
Arpita Dutt - Zacks Investment Research - Tue Mar 29, 9:30AM CDT
Americans are charged more for Medivation's (MDVN) prostate cancer drug, Xtandi, compared to countries like Sweden, Japan and Canada.
MDVN: 80.56 (+0.20), VRX: 29.03 (-1.22)

Amgen Kyprolis' Label Expanded, Repatha Approved in Japan
Zacks Equity Research - Zacks Investment Research - Fri Jan 22, 3:30PM CST
The label for Amgen's (AMGN) Kyprolis has been expanded in the U.S. and accelerated approval has been converted to full approval; Repatha gains approval in Japan.
AMGN: 170.06 (-0.70), ANIK: 47.24 (-0.21), CELG: 106.74 (-0.28)

Where We Are Headed - Featured Research on Airbus Group, Astellas Pharma, Brambles and Detour Gold
ACCESSWIRE - Fri Jan 22, 8:05AM CST
NEW YORK, NY / ACCESSWIRE / January 22, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Airbus Group SE (OTC: EADSY), Astellas Pharma Inc. (OTC: ALPMY), Brambles Ltd. (OTC: BXBLY) and Detour Gold Corp. (OTC: DRGDF). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.

Ironwood Highlights Strategic Objectives, Provides Outlook
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 3:25PM CST
Ironwood Pharmaceuticals (IRWD) provided a comprehensive overview of its initiatives by highlighting three- and five-year operational and financial goals.
AGN: 234.54 (-2.45), IRWD: 13.34 (-0.08), AZN: 32.81 (-0.40)

Vical's VL-2397 Gets Orphan Status for Invasive Aspergillosis
Zacks Equity Research - Zacks Investment Research - Thu Jan 07, 1:50PM CST
Vical's (VICL) antifungal candidate, VL-2397, was granted Orphan Drug designation for the treatment of patients with invasive aspergillosis.
VICL: 3.80 (-0.05), HZNP: 18.80 (-0.21), LGND: 103.31 (-1.00)

Ocata Therapeutics Almost Doubled in November -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Fri Dec 04, 3:03PM CST
What: Shares of eye-disease-focused  Ocata Therapeutics posted a huge 88% gain during the month of November after the company accepted a buyout offer for a healthy premium, according to data from S&P Capital IQ . So what:  Early in the...
OCAT: 8.47 (+0.01)

Ironwood/Astellas Report Positive Phase III Data on Linzess
Zacks Equity Research - Zacks Investment Research - Tue Dec 01, 3:55PM CST
Ironwood Pharmaceuticals (IRWD) and Astellas reported positive top-line phase III data on Linzess; Astellas will file for its approval in Japan in 2016.
AGN: 234.54 (-2.45), IRWD: 13.34 (-0.08), ACHN: 8.26 (-0.10)

Mallinckrodt (MNK) Sells Contrast Media & Delivery Systems
Zacks Equity Research - Zacks Investment Research - Mon Nov 30, 3:55PM CST
Mallinckrodt plc (MNK) announced that it has completed the previously announced divestiture of its global contrast media and delivery systems (CMDS) business to Guerbet for approximately $270 million.
MNK: 74.54 (-0.51), MYL: 42.36 (-0.39), CORT: 5.33 (-0.08)

Roche-Exelixis' Cotellic-Zelboraf Combination Gets EC Nod
Zacks Equity Research - Zacks Investment Research - Thu Nov 26, 12:20PM CST
Roche (RHHBY) received good news when the European Commission (EC) approved its skin cancer drug Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib).
LLY: 77.75 (-0.02), EXEL: 11.15 (+0.11)

Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 25, 9:28AM CST
Image source: Johnson & Johnson. Healthcare conglomerate Johnson & Johnson 's share price may be up only marginally since the week began, but make no mistake about it: The week couldn't have possibly started off better for its long-term...
MDVN: 80.56 (+0.20), JNJ: 119.34 (-0.13), AMGN: 170.06 (-0.70), CELG: 106.74 (-0.28)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 99

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 27

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 349

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 235

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 335

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 254

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 148

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 489

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 241

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Albion KAY VCT PLC's Strong Half-Year Performance Review

Updated Category News Views 95

Overview of Albion KAY VCT PLC Albion KAY VCT PLC plays a critical role in the investment landscape. The Company has recently published its Half-yearly Financial Report, which has garnered significant interest from both shareholders and potential investors. This report provides an in-depth look at the Company’s operations and financial condition over the six months...

Continue Reading
BlackRock Inc. Acknowledges Significant Stake in Syensqo

Updated Category News Views 160

Participation Notification by BlackRock Inc. In a recent communication, BlackRock Inc. has informed Syensqo of their increase in voting rights ownership, surpassing the critical threshold of 3%. This change is attributed to recent acquisitions or disposals of voting securities, which is in line with European transparency regulations. Details of the Notification The...

Continue Reading
Black Kite Unveils Innovative Global AI Risk Assessment Nexus

Updated Category News Views 204

Black Kite Launches Groundbreaking AI Assessment Framework Black Kite's GA³™ framework addresses a significant void in current global assurance frameworks. It creates a comprehensive standard that adapts to the ever-changing AI threat landscape. Importance of AI Risk Management Frameworks As cyber threats evolve, organizations face challenges in third-party risk...

Continue Reading
Purdue University Leads All-Boilermaker Mission with Virgin Galactic

Updated Category News Views 255

Purdue University Embarks on a Landmark Space Mission Building upon its rich legacy in space exploration, Purdue University is poised to undertake a remarkable journey — an all-Boilermaker crew will participate in a Virgin Galactic suborbital spaceflight known as Purdue 1. Set to launch in the near future, this mission opens up new avenues for academic exploration in...

Continue Reading
LP Building Solutions Provides Update on Q3 2024 Earnings Call

Updated Category News Views 77

LP Building Solutions Reveals Q3 2024 Earnings Call Details LP Building Solutions (NYSE: LPX), a prominent player in the building materials sector, has officially announced the schedule for its earnings conference call, set for an upcoming Tuesday. This anticipated event will highlight the financial results for the third quarter of 2024. Important Conference Call...

Continue Reading